The Programmers Approach to Real World Data and Using Real World Evidence in Research and Healthcare

by MMS Holdings and MichBio.org

This webinar is intended to help guide individuals towards a better understanding of core concepts and requirements for using real-world data (RWD). Here, we will delve into how one can derive and utilize real-world evidence (RWE) in drug development, from the perspective of a clinical trial programmer/data analyst. We will discuss the potential opportunities that can generate RWD to improve the safety, efficiency, and quality in a clinical paradigm. The knowledge shared in this presentation echoes the regulatory guidance’s for use of RWE. Evolving standards that are necessary to make the most out of RWD, demonstration projects, and first-hand experience with some technical tools will be discussed. Combining it all together should provide the tools and knowledge to navigate more confidently through this less explored, but complex landscape of RWD and RWE.

Speakers include:

  • Narasimha Ayyalas, Manager, Statistical Programming, MMS Holdings
  • Aditya Gadiko, Senior Clinical Programmer, MMS Holdings
  • Susheel Arkala, Manager, Statistical Programming, MMS Holdings
  • Chris Hurley, Associate Director, Data Sciences, MMS Holdings
  • Ravi Yandamuri, Principal Clinical Programmer, MMS Holdings

Suggested For You

perspectives

July 30th, 2024

The Critical Role of Quality Control (QC) – Medical Writing and Beyond

perspectives

July 23rd, 2024

PSI 2024 Ignited Conversations on External Data Sources, Requirements for Estimands, and Bayesian Methodology for Statisticians in Pharma

perspectives

July 16th, 2024

Key Steps to Successful CMC Authoring of IND and IMPD Submissions

perspectives

July 9th, 2024

Managing RTOR Submissions: How to Run a Successful Race from the Top Line Starting Line

perspectives

July 2nd, 2024

Part 1: RWD Noninterventional Study Design and FDA Engagement Opportunity for Early Stage Oncology

perspectives

June 21st, 2024

Peer-Reviewed Journal Articles: The Crucial Role of Publication in the Pharmaceutical Industry

perspectives

June 14th, 2024

A Structured Approach to Benefit-Risk Assessment Throughout Product Development in the Pharmaceutical Industry

perspectives

June 6th, 2024

Datacise and Diversity in Patient Enrollment: Combining Geospatial and Demographic Data to Aid Site Selection

perspectives

May 29th, 2024

Confined Deferrals in Clinical Trial Applications: Anticipating the Revised EU CTR Transparency Rules

perspectives

May 21st, 2024

Psychedelics and Regulatory Considerations Part II: A Shift in Lexicon and Implications of “Nonmedical Use” On Labelling

perspectives

May 10th, 2024

Psychedelics in Drug Development and Regulatory Considerations Part I: Benefit-Risk

perspectives

April 29th, 2024

Validation of Clinical Dashboards for Decision Making